| __timestamp | Rhythm Pharmaceuticals, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1213000 | 1499100000 |
| Thursday, January 1, 2015 | 3425000 | 1923500000 |
| Friday, January 1, 2016 | 6311000 | 2351400000 |
| Sunday, January 1, 2017 | 9518000 | 2564000000 |
| Monday, January 1, 2018 | 28080000 | 2397300000 |
| Tuesday, January 1, 2019 | 36550000 | 2503400000 |
| Wednesday, January 1, 2020 | 46125000 | 3344600000 |
| Friday, January 1, 2021 | 68486000 | 4529200000 |
| Saturday, January 1, 2022 | 92032000 | 4179100000 |
| Sunday, January 1, 2023 | 117532000 | 4650100000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Viatris Inc. and Rhythm Pharmaceuticals, Inc. have taken distinct paths in optimizing these costs. From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023. In contrast, Rhythm Pharmaceuticals, Inc. started with a modest $1.2 million in 2014, escalating to around $117 million by 2023. This represents a staggering increase of nearly 9,600% over the period. While Viatris Inc.'s expenses grew by about 210%, their scale and market presence justify the higher absolute numbers. The data suggests that while Viatris Inc. operates on a larger scale, Rhythm Pharmaceuticals, Inc. is rapidly expanding its operational footprint, reflecting its growth trajectory in the pharmaceutical sector.
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.